We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




RNA Amplification Technology for Small Samples

By Biotechdaily staff writers
Posted on 07 Nov 2002
New technology has been developed for performing RNA amplification for gene expression analysis from very small samples.

The technology can be used to successfully amplify mRNA transcripts from samples less than 1ng. More...
Called Ribo-SPIA, the system will enable scientists to significantly expand the scope of their research by enabling them to perform studies on very small amounts of precious samples that previously could not be readily analyzed.

Ribo-SPIA(TM) makes a cDNA copy of the original mRNA sequence and then produces an amplified product. This DNA product is more stable than the RNA product generated by existing methods, such as the T7-based (Eberwine) RNA amplification method, resulting in more efficient and reproducible labeling and analysis. Ribo-SPIA can achieve up to 1,000 or more copies in less than four hours, compared to two to three days when using other technologies.

The system is well-suited for quantitative gene expression analysis of total RNA derived from tissue biopsies, laser captured micro-dissected (LCM) material, and other precious samples. The technology generates enough material for hundreds of gene-specific TaqMan(R) assays or global expression profiling on several microarrays from less than 20 ng of total RNA input for a single amplification reaction.

"Our Ribo-SPIA technology will enable scientists to drastically reduce the amount of sample required to conduct gene expression profiling, while maintaining the fidelity required to make this analysis meaningful,” said Nurith Kurn, Ph.D., chief scientific officer of NuGen Technologies (San Carlos, CA, USA), which developed the technology. "Unlike current methods, Ribo-SPIA is a very simple and rapid process that is highly reproducible and amenable to automation for high-throughput applications.”




Related Links:
NuGen Technologies

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.